MagForce (MF6) - 2017 lays foundation for 2018 progress

11:47 EDT 17 May 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - MagForce: MagForce continues to execute its two-pronged strategy. With €35m now available in financing from the EIB, MagForce can now roll out its Nanotherm devices outside of Germany for the treatment of glioblastoma multiforme (GBM) patients. Plans for 2018 to expand into Poland and Italy reflect the high levels of enquires coming from both countries. In the US, the first patient is expected to enrol into the pivotal clinical trial for prostate cancer in Q218, following the investigational device exemption (IDE) approval in February 2018. We value MagForce at €11.7/share.

Original Article: MagForce (MF6) - 2017 lays foundation for 2018 progress


More From BioPortfolio on "MagForce (MF6) - 2017 lays foundation for 2018 progress"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...